Author

Christopher R. M. Asquith

University of Eastern FinlandORCID 0000-0001-5871-3458Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 5 Approach:experimental assay· 4 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

Tuomo LaitineniD· 5 shared Antti PosoiD· 3 shared Carrow I. WellsiD· 2 shared Gary L. JohnsoniD· 2 shared Graham J. TizzardiD· 2 shared Michael P. EastiD· 2 shared Timothy Mark WillsoniD· 2 shared William J. ZuercheriD· 2 shared

Activity by Year

2019-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersPharmacology & Toxicology

Tuomo LaitinenORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintAug 20, 2026

Discovery and optimization of the next generation of cell active Protein Kinase Novel 3 (PKN3) inhibitors

Eleni Georgiou, Tuomo Laitinen, Antti Poso…·Christopher R. M. Asquith

This study identifies and optimizes a submicromolar PKN3 inhibitor, 6e (URS03-06), for cellular biology research.

DOI 10.64898/2026.08.20.745975

experimental assaydrug response / drug discovery

𝕏 PostBluesky

MicrobiologyNature CommunicationsPeer-reviewedJul 10, 2025

PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2

Marwah Karim, Manjari Mishra, Chieh‐Wen Lo…·Shirit Einav

RMC-113 inhibits PIP4K2C and PIKfyve, reversing SARS-CoV-2-induced autophagic flux impairment and showing antiviral effects.

19 citationstop 1%

humanorganoid / primary culture

𝕏 PostBluesky

Pharmacology & ToxicologyEuropean Journal of Medicinal ChemistryPeer-reviewedApr 1, 2024

Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships

Christopher R. M. Asquith, Michael P. East, Tuomo Laitinen…·Gary L. Johnson

The paper identifies and optimizes narrow-spectrum TLK2 inhibitors using QSAR analysis and structural studies.

4 citations

statistical modeldrug response / drug discovery

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintMay 7, 2019

Development of SGC-GAK-1 as an orally active in vivo probe for cyclin G associated kinase through cytochrome P450 inhibition

Christopher R. M. Asquith, James M. Bennett, Lianyong Su…·William J. Zuercher

The paper develops SGC-GAK-1 as an orally active in vivo probe for GAK by using cytochrome P450 inhibition to improve its metabolic stability and plasma exposure.

DOI 10.1101/629220

mouseexperimental assay

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintFeb 11, 2019

Design and evaluation of novel 4-anilinoquinolines and quinazolines as EGFR inhibitors in lung cancer and chordoma

Christopher R. M. Asquith, Kaitlyn A. Maffuid, Tuomo Laitinen…·William J. Zuercher

The paper designs and evaluates novel 4-anilinoquinolines and quinazolines as EGFR inhibitors, identifying a potent compound for lung cancer and chordoma treatment.

DOI 10.1101/545525

humanexperimental assay

𝕏 PostBluesky